

**Metsios, G. and Koutedakis, Y. and Veldhuijzen van Zanten, J. and Stavropoulos-Kalinoglou, A. and Vitalis, P. and Duda, J. and Ntoumanis, N. et al. 2015. Cardiorespiratory fitness levels and their association with cardiovascular profile in patients with rheumatoid arthritis: a cross-sectional study. *Rheumatology*. 54 (12): pp. 2215-2220.**

**Short Title:** Cardiorespiratory Fitness and CVD in RA

**Authors:** Metsios GS<sup>1, 2, 3</sup>, Koutedakis Y<sup>1, 3</sup>, Veldhuijzen van Zanten JJCS<sup>2, 4</sup>, Stavropoulos-Kalinoglou A<sup>3</sup>, Vitalis P<sup>1</sup>, Duda JL<sup>4</sup>, Ntoumanis N<sup>4</sup>, Rouse PC<sup>4</sup>, Kitas GD<sup>2, 4</sup>.

<sup>1</sup> Department of Physical Activity Exercise and Health, University of Wolverhampton, Walsall, West Midlands, United Kingdom.

<sup>2</sup> Department of Rheumatology, Dudley Group NHS Foundation Trust, Russell's Hall Hospital, Dudley, West Midlands, United Kingdom.

<sup>3</sup> Research Institute in Physical Performance and Rehabilitation, Centre for Research and Technology – Thessaly, Trikala, Greece.

<sup>4</sup> School of Sport, Exercise and Rehabilitation Sciences, University of Birmingham, Birmingham, United Kingdom

**Corresponding Author:**

Dr George S. Metsios, BSc, MSc, PhD  
Reader in Clinical Exercise Physiology  
University of Wolverhampton, Walsall Campus, Room: WA 210  
Gorway Road, Walsall, WS1 3BD  
Email: [G.Metsios@wlv.ac.uk](mailto:G.Metsios@wlv.ac.uk)  
Tel: +44 (0) 1902 323104  
Fax: +44 (0) 1902 323295

**Word Count:** 1937

**Keywords:** exercise, physical activity, cardiorespiratory fitness, cardiovascular disease, inflammation, rheumatoid arthritis

## Abstract

**Objectives:** This cross-sectional study investigated the association of different physical fitness levels (assessed by the maximal oxygen uptake (VO<sub>2</sub>max) test) with cardiovascular disease (CVD) risk factors in patients with rheumatoid arthritis (RA).

**Methods:** 150 RA patients were assessed for cardiorespiratory fitness with a VO<sub>2</sub>max test and based on this were split in three groups using the 33<sup>rd</sup> (18.1 ml.kg.min<sup>-1</sup>) and 66<sup>th</sup> (22.4 ml.kg.min<sup>-1</sup>) centiles. Classical and novel CVD risk factors (blood pressure, body fat, insulin resistance, cholesterol, triglycerides, high density lipoprotein-HDL, physical activity, C-Reactive Protein-CRP, fibrinogen and white cell count), 10-year CVD risk, disease activity (disease activity score 28-DAS28) and severity (health assessment questionnaire-HAQ) were assessed in all cases.

**Results:** Mean VO<sub>2</sub>max for all RA patients was 20.9±5.7 ml.kg.min<sup>-1</sup>. Ten-year CVD risk (p=0.003), systolic blood pressure (p=0.039), HDL (p=0.017), insulin resistance and body fat (both at p<0.001), CRP (p=0.005), white blood cell count (p=0.015) and fibrinogen (p<0.001) were significantly different between the VO<sub>2</sub>max tertiles favouring the group with the higher VO<sub>2</sub>max levels. In multivariate analyses of variance, VO<sub>2</sub>max was significantly associated with body fat (p<0.001), HDL (p=0.007), insulin resistance (p<0.003) and 10-year CVD risk (p<0.001), even after adjustment for DAS28, HAQ and physical activity.

**Conclusions:** VO<sub>2</sub>max levels are alarmingly low in RA patients. Higher levels of VO<sub>2</sub>max associate with a better cardiovascular profile in this population. Future studies need to focus on developing effective behavioural interventions to improve cardiorespiratory fitness in RA.

## Key messages

1. Cardiorespiratory fitness is alarmingly low in RA patients
2. Cardiovascular profile and 10-year CVD risk is worse in patients with low cardiorespiratory fitness
3. Cardiorespiratory fitness may be a good surrogate CVD marker in RA

**Keywords:** exercise, physical activity, cardiorespiratory fitness, cardiovascular disease, inflammation, rheumatoid arthritis, insulin resistance, body fat, cholesterol, risk factors

## **Introduction**

Rheumatoid arthritis (RA) associates with an increased risk for cardiovascular disease (CVD) (1) attributed to both the deleterious effects of inflammation on the vasculature and to the increased prevalence of traditional CVD risk factors (2-5). Increased physical activity and/or exercise may associate with improved CVD risk profile in both healthy and diseased populations; this is indicated by the robust inverse relationship of CVD morbidity and mortality with cardiorespiratory fitness, as measured by the “gold standard” method, the maximal oxygen uptake (VO<sub>2</sub>max) test (6). Patients with RA have significantly lower levels of VO<sub>2</sub>max compared to healthy counterparts (7) but the association of VO<sub>2</sub>max and CVD risk has never been investigated in this population. The aim of the present cross-sectional study was to investigate the association of VO<sub>2</sub>max with both traditional and novel CVD risk factors and 10-year CVD risk in a well-characterised population of patients with RA.

## **Methods**

### **Participants**

One hundred and fifty patients were recruited from the Dudley Group NHS Foundation Trust, UK. The study was approved by the local NHS Research Ethics Committee and a detailed verbal and written description for the procedures involved was offered to all participants, according to the declaration of Helsinki. Patients' records were reviewed before requesting participation. Inclusion criteria were: fulfilling the American College of Rheumatology RA criteria and being on stable treatment for at least three months. Exclusion criteria were: previous/present CVD (e.g. cardiomyopathies, arrhythmias), cerebrovascular disease, diabetes, restrictive/obstructive lung disease, known malignancy, pregnancy, current infection, and hyper- or hypothyroidism, recent joint surgery (preceding six months), amputation, functional comorbidities incompatible with VO<sub>2</sub>max testing.

## Procedures

Patients visited our laboratory after a 12h overnight fast for collection of blood samples, demographic, anthropometric and disease-related characteristics: standing height was measured with a Seca Stadiometer, body mass and composition via bioelectrical impedance (Tanita BC418-MA, Japan), disease activity via the erythrocyte sedimentation rate (ESR), C-reactive protein (CRP) and the 28 joint Disease Activity Score (DAS28), and disease severity via the Stanford Health Assessment Questionnaire (HAQ). Classical and novel CVD risk profile included: triglycerides, total cholesterol, high- and low-density lipoprotein (HDL and LDL) (Vitros® 5.1, USA), physical activity (International Physical Activity Questionnaire), glucose and insulin (Immunolite 2000 Analyser, USA) from which the homeostasis model assessment (HOMA) was calculated, blood pressure, family history, smoking, CRP (Vitros® 5.1 FS, USA), haemoglobin and white cell count (ADVIA® 120, Germany) and fibrinogen (IL Futura Advance analyser, UK). 10-year CVD risk was calculated using the Framingham score.

Participants returned within three days to perform an individualised VO<sub>2</sub>max test protocol with electrocardiography (ECG) after taking into account their physical abilities and the American Heart Association guidelines using a previously published protocol (8) and specific contraindications for terminating the test (9). The VO<sub>2</sub>max test was performed on a treadmill using a calibrated breath-by-breath system (Metalyzer 3B, CORTEX, Germany). Based on the results of the VO<sub>2</sub>max test, participants were divided into three groups using the 33<sup>rd</sup> (18.1 ml.kg.min<sup>-1</sup>) and 66<sup>th</sup> (22.4 ml.kg.min<sup>-1</sup>) centiles (10). To determine the number of participants needed per group, we used RA (8) and age-matched normal population VO<sub>2</sub>max data, and calculated that 44 patients were needed (90% power and 5% alpha error level). To account for potential drop-out we recruited 150 patients. Given the relevant VO<sub>2</sub>max data

from the general population (9) these groups reflected unfit vs. moderately unfit vs. average fitness groups, respectively.

### *Statistical Analyses*

Kolmogorov-Smirnov tests were performed to investigate the distribution of all variables. Chi-square analyses were conducted to investigate differences amongst the VO2max tertiles for categorical variables (e.g. gender and medication). One-way analyses of variance (ANOVA) with Bonferroni correction for adjusting the number of multiple comparisons or Kruskal-Wallis tests were utilised, according to distribution, to investigate differences between VO2max tertiles. After controlling for age, gender and physical activity, multivariate ANOVA (MANOVA) with Sidak correction were initially utilised to investigate the association of VO2max levels (as a categorical variable with the three groups) with CVD risk factors. Thereafter, disease activity and severity variables were also utilised in the same models to investigate whether the association of VO2max with CVD factors and 10-year CVD risk persisted. For the MANOVAs, log transformations were conducted on all the variables that were not normally distributed. The adjusted mean differences [with confidence intervals (95% CI)] were also reported for the variables that were significantly different. The level of significance was set at  $p < 0.05$ .

### **Results**

Of the 150 patients that agreed to participate, six did not attend. Mean VO2max for the entire cohort was  $20.9 \pm 5.7$  ml.kg.min<sup>-1</sup> and was significantly different between the tertiles, i.e. unfit:  $15.4 \pm 1.9$  vs. moderately unfit:  $20.2 \pm 1.3$  vs. average:  $27.1 \pm 4.7$  ml.kg.min<sup>-1</sup>, ( $p < 0.001$ ). Significant differences were detected in age between the tertiles (Table 1,  $p = 0.035$ ) but not gender [Table 1,  $p = 0.095$ ] or physical activity [Table 2,  $p = 0.051$ ]. The anthropometric and disease-related characteristics of the three RA groups appear in Table 1.

\*\*\*Table 1 near here\*\*\*

#### Associations between cardiovascular profile and VO2max

Significant differences between the three groups were detected in systolic blood pressure, HDL, insulin resistance and body fat, CRP, fibrinogen, and white blood cell count, as well as 10-year CVD risk (Table 2).

#### Adjusted associations between cardiovascular profile and VO2max

Classical CVD risk factors: After correction for age, gender and physical activity, VO2max levels significantly associated with body fat ( $F_{1,107}=16.7$ ,  $p<0.001$ ), HOMA ( $F_{1,107}=6.0$ ,  $p=0.003$ ) and HDL ( $F_{1,107}=5.3$ ,  $p=0.007$ ) but not systolic blood pressure ( $p>0.05$ ). After further adjustment for DAS28 and HAQ, VO2max significantly associated with: a) body fat ( $F_{1,107}=15.7$ ,  $p<0.001$ ), which was related to the differences reported between the average vs. unfit groups [mean difference (95% CI)=10.9(6.1 to 15.7)%,  $p<0.001$ ] and average vs. moderately unfit groups [mean difference (95% CI) =6.8(2.2 to 11.3)%,  $p=0.001$ ], and b) HOMA ( $F_{1,107}=4.4$ ,  $p=0.016$ ) and HDL ( $F_{1,107}=5.6$ ,  $p=0.005$ ) which was related to the differences that were observed in average vs. unfit group [mean difference (95% CI): HOMA=0.52(0.09 to 0.95),  $p=0.012$  and HDL=0.23(0.05 to 0.41)mmol/L,  $p=0.007$ ].

Novel CVD risk factors: After correction for age, gender and physical activity, VO2max levels revealed significant associations with CRP ( $F_{1,109}=3.8$ ,  $p=0.025$ ) and fibrinogen ( $F_{1,109}=18.5$ ,  $p<0.001$ ) but not white blood cells ( $p=0.087$ ). For CRP, this association was related to the differences between the average vs. unfit group [mean difference (95% CI) =0.78(0.09 to 1.47)mg/L,  $p=0.021$ ]. Further correction for DAS28 and HAQ, did not eliminate the significant association between VO2max levels and fibrinogen ( $p<0.001$ ): these

associations were related to the differences between the unfit vs. average [mean difference (95% CI)=1.2(0.64 to 1.80)g/dL,  $p<0.001$ ] as well as the moderately unfit vs. average groups [mean difference (95% CI)=0.64(0.06 to 1.22)g/dL,  $p=0.024$ ].

10-year CVD risk: After adjustment for age, gender and physical activity, the levels of VO<sub>2</sub>max significantly associated with the 10-year CVD risk ( $F_{1,123}=11.2$ ,  $p<0.001$ ) while further correction for DAS28 and HAQ in this model did not alter this association ( $F_{1,123}=10.8$ ,  $p<0.001$ ). This was related to the differences that were detected between the average vs. unfit [mean difference (95% CI)=1.23(0.58 to 1.88)yrs,  $p<0.001$ ] as well as the average vs. moderately unfit patients [mean difference (95% CI)=0.81(0.18 to 1.45)yrs,  $p=0.007$ ].

\*\*\*Table 2 near here\*\*\*

## Discussion

RA patients with higher VO<sub>2</sub>max had better CVD risk profile and lower 10-year CVD risk compared to those with lower VO<sub>2</sub>max levels. Substantial evidence demonstrates a strong inverse association between CVD morbidity and mortality with VO<sub>2</sub>max (11, 12) highlighting the important role of fitness for health and longevity. RA patients repeatedly demonstrate significantly lower VO<sub>2</sub>max levels compared to healthy counterparts, most likely related to their low levels of physical activity (7, 13) and increased disease activity/severity; for example, a fit RA patient may stop the test potentially because of disease-related pain and physical dysfunction and not cardiorespiratory limitations. The low overall VO<sub>2</sub>max levels observed in this study, is an alarming finding that could be linked with the increased incidence of CVD-related death in RA, however, appropriate longitudinal studies are necessary to confirm this. Our results suggest significant differences between RA patients, classified according to fitness level, in a variety of classic and novel CVD risk

factors, as well as the 10-year CVD risk. As such, it seems reasonable to suggest that increased cardiorespiratory fitness may provide a protective role against CVDs in this population, which is similar to what is seen in the normal population (14, 15) or other rheumatic diseases (16).

Further analyses demonstrated that, after controlling for disease activity and severity, VO<sub>2</sub>max levels significantly associated with body fat, HDL and insulin resistance. RA patients experience a condition termed rheumatoid cachexia which is characterised by a significant increase in adiposity and decreased muscle mass; as such at the same weight a patient with RA may have an altered body composition compared to a healthy normal individual that favours an inferior cardiovascular profile (17). This condition seems to be mediated by both inflammation and physical inactivity (17). Studies in RA have previously shown that obesity associates with both low HDL and insulin resistance (18). Moreover, inflammation which is overexpressed in both obesity and RA, affects glucose metabolism and enzymes fundamental to HDL metabolism, promoting the development of insulin resistance and atherosclerosis (19). The interplay of these factors with physical inactivity may be one of several factors that explain the increased incidence of CVD and CVD death in RA.

Exercise is the predominant intervention to increase VO<sub>2</sub>max. Even in a disease such as RA which is characterised by significant disability, pain and fatigue, exercise is recommended and in fact, can even ameliorate disease-related symptoms (20) and the calculated risk for CVD. Therefore, RA patients can and should exercise but they consistently report lower levels of fitness compared to the healthy population (7, 16). The effects of exercise on improving disease activity and cardiovascular risk factors have also been shown in axial spondyloarthritis, another chronic inflammatory joint disease (21). Research investigating ways of increasing and maintaining physical activity and reducing sedentary behaviour is necessary in RA patients.

**Deleted:** this population



This study is limited by not evaluating VO2max levels of an equivalent age-gender matched population, its cross-sectional design, and the non-inclusion of patients with pulmonary fibrosis/nodules or other significant extra-articular features (as well as keeping a detailed record of non-included patients). Patients with poor mobility were also excluded, possibly introducing a positive bias in the present study. This would suggest that we have selected the “fittest” RA patients herein who still demonstrated that their VO2max levels are alarmingly low. Nevertheless, this is the first study that has explored the associations between VO2max and CVD risk factors with such a large sample of RA patients using appropriate power calculations and adjustment for several potential confounders. We conclude that overall VO2max levels are low in both female and male RA patients, and that lower VO2max levels associate with inferior CVD profile and higher 10-year CVD event risk.

### **Acknowledgements**

We would like to thank Jacqueline Smith and Sue Cadman who work in the Russells Hall Hospital biomedical science laboratory and were responsible for all blood analyses.

### **Conflict of Interest Statement**

There authors declare no conflict of interest.

## References

1. Avina-Zubieta JA, Thomas J, Sadatsafavi M, Lehman AJ, Lacaille D. Risk of incident cardiovascular events in patients with rheumatoid arthritis: a meta-analysis of observational studies. *Ann Rheum Dis*. 2012;71(9):1524-9.
2. Panoulas VF, Douglas KM, Millionis HJ, Stavropoulos-Kalinglou A, Nightingale P, Kita MD, et al. Prevalence and associations of hypertension and its control in patients with rheumatoid arthritis. *Rheumatology (Oxford)*. 2007;46(9):1477-82.
3. Sandoo A, van Zanten JJ, Metsios GS, Carroll D, Kitas GD. The endothelium and its role in regulating vascular tone. *The open cardiovascular medicine journal*. 2010;4:302-12.
4. Stavropoulos-Kalinoglou A, Metsios GS, Koutedakis Y, Kitas GD. Obesity in rheumatoid arthritis. *Rheumatology (Oxford)*. 2011;50(3):450-62.
5. Toms TE, Panoulas VF, Smith JP, Douglas KM, Metsios GS, Stavropoulos-Kalinoglou A, et al. Rheumatoid arthritis susceptibility genes associate with lipid levels in patients with rheumatoid arthritis. *Ann Rheum Dis*. 2011;70(6):1025-32.
6. Sui X, LaMonte MJ, Laditka JN, Hardin JW, Chase N, Hooker SP, et al. Cardiorespiratory fitness and adiposity as mortality predictors in older adults. *JAMA*. 2007;298(21):2507-16.
7. Metsios GS, Stavropoulos-Kalinoglou A, Veldhuijzen van Zanten JJ, Treharne GJ, Panoulas VF, Douglas KM, et al. Rheumatoid arthritis, cardiovascular disease and physical exercise: a systematic review. *Rheumatology (Oxford)*. 2008;47(3):239-48.
8. Stavropoulos-Kalinoglou A, Metsios GS, Veldhuijzen van Zanten JJ, Nightingale P, Kitas GD, Koutedakis Y. Individualised aerobic and resistance exercise training improves cardiorespiratory fitness and reduces cardiovascular risk in patients with rheumatoid arthritis. *Ann Rheum Dis*. 2013;72(11):1819-25.
9. ACSM. Guidelines for exercise testing and prescription. 7 ed. Philadelphia: Lippincott Williams & Wilkins; 2005.
10. Metsios GS, Stavropoulos-Kalinoglou A, Panoulas VF, Wilson M, Nevill AM, Koutedakis Y, et al. Association of physical inactivity with increased cardiovascular risk in patients with rheumatoid arthritis. *Eur J Cardiovasc Prev Rehabil*. 2009;16(2):188-94.
11. Stevens J, Cai J, Evenson KR, Thomas R. Fitness and fatness as predictors of mortality from all causes and from cardiovascular disease in men and women in the lipid research clinics study. *Am J Epidemiol*. 2002;156(9):832-41.
12. Wei M, Kampert JB, Barlow CE, Nichaman MZ, Gibbons LW, Paffenbarger RS, Jr., et al. Relationship between low cardiorespiratory fitness and mortality in normal-weight, overweight, and obese men. *JAMA*. 1999;282(16):1547-53.
13. Tierney M, Fraser A, Kennedy N. Physical activity in rheumatoid arthritis: a systematic review. *J Phys Act Health*. 2012;9(7):1036-48.
14. Cornelissen VA, Smart NA. Exercise training for blood pressure: a systematic review and meta-analysis. *J Am Heart Assoc*. 2013;2(1):e004473.
15. Kodama S, Tanaka S, Saito K, Shu M, Sone Y, Onitake F, et al. Effect of aerobic exercise training on serum levels of high-density lipoprotein cholesterol: a meta-analysis. *Arch Intern Med*. 2007;167(10):999-1008.
16. Ayan C, Martin V. Systemic lupus erythematosus and exercise. *Lupus*. 2007;16(1):5-9.
17. Summers GD, Metsios GS, Stavropoulos-Kalinoglou A, Kitas GD. Rheumatoid cachexia and cardiovascular disease. *Nature reviews Rheumatology*. 2010;6(8):445-51.

18. Dessein PH, Joffe BI, Stanwix AE. Inflammation, insulin resistance, and aberrant lipid metabolism as cardiovascular risk factors in rheumatoid arthritis. *The Journal of rheumatology*. 2003;30(7):1403-5.
19. Sattar N, McCarey DW, Capell H, McInnes IB. Explaining how "high-grade" systemic inflammation accelerates vascular risk in rheumatoid arthritis. *Circulation*. 2003;108(24):2957-63.
20. Baillet A, Zeboulon N, Gossec L, Combescure C, Bodin LA, Juvin R, et al. Efficacy of cardiorespiratory aerobic exercise in rheumatoid arthritis: meta-analysis of randomized controlled trials. *Arthritis Care Res (Hoboken)*. 2010;62(7):984-92.
21. Sveaas SH, Berg IJ, Provan SA, Semb AG, Hagen KB, Vollestad N, et al. Efficacy of high intensity exercise on disease activity and cardiovascular risk in active axial spondyloarthritis: a randomized controlled pilot study. *PLoS One*. 2014;9(9):e108688.

**Table 1.** Anthropometric and disease-related characteristics [either in mean±std or median(interquartile range)] of the total population and fitness sub-groups.

	Total RA (n=144)	Unfit (n=47)	Moderately Unfit (n=48)	Average Fitness (n=49)	<b>P</b>
VO2max (ml.kg.min <sup>-1</sup> )	20.9±5.7	15.4±1.9**	20.2±1.3**	27.1±4.7	<b>&lt;0.001</b>
Age (yrs)	54.4±11.7	54.7±13.4	57.3±10.3	51.2±10.6	<b>0.035</b>
Gender-females (n)	101	37	35	29	0.095
Anthropometric					
Height (cm)	1.71(1.63-1.71)	1.66(1.59-1.71)	1.64(1.59-1.73)	1.66(1.61-1.72)	<b>0.018</b>
Weight (kg)	76.8(65.5-90.0)	86.3(70.5-97.7)	77.5(70.5-86.8)	69.2(59.3-82.0)	<b>&lt;0.001</b>
Fat-Free Mass (kg)	49.0(42.0-58.0)	49.0(42.2-59.7)	47.0(42.0-58.0)	49.0(42.0-60.0)	0.944
RA characteristics					
Disease Duration (yrs)	6.0(3.0-10.0)	5.0(2.0-6.5)	7.0(4.0-14.5)	5.0(3.0-7.5)	<b>0.046</b>
DAS28	3.2(2.3-4.5)	3.2(2.1-4.6)	3.0(2.3-4.0)	3.3(2.3-4.5)	0.817
ESR (mm1st hr)	11.0(5.0-21.0)	19.0(12.0-32.7)	10.0(7.0-21.5)	5.0(2.0-10.2)	<b>&lt;0.001</b>
HAQ	0.58(0.13-1.12)	0.79(0.17-1.13)	0.52(0.16-1.21)	0.35(0.1-1.0)	0.617
Medication n(%)					
DMARDs	73(50%)	24(33%)	28(38%)	21(29%)	0.414
Anti-TNFa	22(15%)	10(45%)	5(23%)	7(32%)	0.350
NSAIDs	50(35%)	17(34)	15(30%)	18(36%)	0.948
Analgesics	57(40%)	20(35%)	18(32%)	19(33%)	0.709

P = differences between groups detected using ANOVA

Significantly different from the Average fitness group (ANOVA with Bonferroni): \*\* p<0.001 and \*p<0.05

Significant values are highlighted in bold.

VO2max=maximal oxygen uptake, BMI=body mass index, DAS28=disease activity score, ESR=erythrocyte sedimentation rate, HAQ=health assessment questionnaire, DMARDs=disease-modifying anti-rheumatic drugs, anti-TNFa=anti tumour necrosis factor alpha, NSAIDs=non-steroidal anti-inflammatory drugs

**Table 2.** Classical CVD risk factors and 10 year CVD risk [either in mean±std or median(range)] of the total population and fitness groups studied .

	Total RA (n=144)	Unfit (n=47)	Moderately Unfit (n=48)	Average Fitness (n=49)	P
<i>Classical Risk Factors</i>					
SBP (mmHg)	132.6±15.9	134.4±15.0	135.6±17.0*	127.9±14.7	<b>0.039</b>
DBP (mmHg)	81.0±9.8	80.4±10.3	82.8±10.4	79.6±8.5	0.4
Triglycerides (mmol/L)	1.1(0.8-1.6)	1.1(0.8-2.1)	1.1(0.0-1.7)	1.1(0.8-1.4)	0.46
Cholesterol (mmol/L)	5.0±1.0	5.1±1.1	5.1±1.1	5.0±0.9	0.916
HDL (mmol/L)	1.4(1.1-1.7)	1.2(1.1-1.6)*	1.3(1.2-1.6)	1.5(1.2-1.8)	<b>0.017</b>
LDL (mmol/L)	3.1(2.5-3.6)	2.7(2.4-3.7)	3.1(2.5-3.6)	3.1(2.6-3.5)	0.847
Glucose (mmol/L)	4.6(4.4-5.0)	4.6(4.3-5.1)	4.7(4.3-5.0)	4.6(4.4-5.0)	0.772
HOMA (mmol/L)	1.5(0.9-2.3)	2.0(1.4-2.4)*	1.5(1.2-2.1)*	0.9(0.6-1.7)	<b>&lt;0.001</b>
BMI (kg/m <sup>2</sup> )	27.8(24.2-31.5)	30.0(26.0-35.0)	27.9(25.3-31.0)	24.5(22.1-27.8)	<b>&lt;0.001</b>
Fat Mass (%)	35.0(30.0-42.0)	41.0(34.8-46.2)	38.0(32.2-42.7)	30.0(25.5-33.9)	<b>&lt;0.001</b>
Physical Activity (MET-min/week)	3109.0 (1085.0-5812.5)	2102.5 (925.5-4447.5)	2830.5 (946.5-6018.7)	3549.0 (1782.0-9759.0)	0.051
Smoking (n)	17	6	4	7	0.912
Family history of CVD (n)	62	23	20	19	0.995
<i>Novel Risk Factors</i>					
CRP (mg/L)	3.6(2.6-8.6)	7.3(3.0-10.7)	4.5(2.7-9.8)	3.0(1.7-4.5)	<b>0.005</b>
vWF (IU/dL)	136(108-181)	138(120-180)	143(103-193)	129.0(88-170)	<b>&lt;0.001</b>
White cell count (b/L)	6.7±2.1	7.3±2.4	6.8±1.9	6.0±1.8	<b>0.015</b>
Hemoglobin (gm/dL)	13.3±1.2	13.1±1.0*	13.4±1.2	13.4±1.4	0.519
10 year CVD risk (%)	7.0 (3.0-13.0)	8.0 (4.0-15.2)	7.0 (4.0-12.9)	4.0 (2.0-7.0)	0.003

P = differences between groups detected using ANOVA

Significantly different from the Average fitness group (ANOVA with Bonferroni): \*\* p<0.001 and \*p<0.05

Significant values are highlighted in bold.

SBP=systolic blood pressure, DBP=diastolic blood pressure, HDL=high density lipoprotein, LDL=low density lipoprotein, HOMA=homeostatic model assessment, CRP=c reactive protein, vWF=von Willebrand factor, CVD cardiovascular disease